In addition, FXa inhibitors are considered standard of care in human beings with non-valvular atrial fibrillation (14), which predisposes to cardiac chamber thrombosis, a condition with similarities to cardiomyopathy-associated cardiac thrombosis in cats. This evidence concerns the gene F10 and cardiomyopathy.